Literature DB >> 16741250

CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

Frank Dicker1, Arnon P Kater, Carlos E Prada, Tetsuya Fukuda, Januario E Castro, Guizhen Sun, Jean Y Wang, Thomas J Kipps.   

Abstract

Intravenous infusion of autologous chronic lymphocytic leukemia (CLL) cells transduced with an adenovirus encoding CD40-ligand (CD154) caused rapid reductions in leukemia-cell counts and lymphnode size. We hypothesized that CD40-ligation via CD154 sensitized CLL cells to death-receptor-mediated apoptosis. We found that CD154-expressing cells induced expression of CD95 and the BH3-interacting-domain death agonist (Bid) in CLL, regardless of whether the leukemia cells had functional p53. Such treatment also induced p73, a p53-related transcription factor regulated by c-Abl kinase, and enhanced the sensitivity to fludarabine (F-ara-A) of CLL cells lacking functional p53. Transduction of CLL cells with an adenovirus encoding p73 also induced Bid and CD95 and enhanced the sensitivity to F-ara-A of p53-deficient CLL cells. However, inhibition of c-Abl with imatinib suppressed CD154-induced expression of p73, p73-induced expression of Bid and CD95, and blocked the sensitization of p53-deficient CLL cells to CD95-mediated or F-ara-A-induced apoptosis. Conversely, CLL cells transduced with an imatinib-resistant c-Abl mutant could be induced by CD154 to express p73 and Bid even when treated with imatinib. These results indicate that CD154 can sensitize leukemia cells to apoptosis via the c-Abl-dependent activation of p73 and mitigate the resistance of p53-deficient CLL cells to anticancer drug therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741250      PMCID: PMC1895435          DOI: 10.1182/blood-2006-04-017749

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

Authors:  R Takimoto; W S El-Deiry
Journal:  Oncogene       Date:  2000-03-30       Impact factor: 9.867

2.  Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells.

Authors:  K Kato; M J Cantwell; S Sharma; T J Kipps
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

3.  CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Authors:  W G Wierda; M J Cantwell; S J Woods; L Z Rassenti; C E Prussak; T J Kipps
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

4.  p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.

Authors:  A R Pettitt; P D Sherrington; G Stewart; J C Cawley; A M Taylor; T Stankovic
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

5.  Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53.

Authors:  I Fillippovich; N Sorokina; M Gatei; Y Haupt; K Hobson; E Moallem; K Spring; M Mould; M A McGuckin; M F Lavin; K K Khanna
Journal:  Oncogene       Date:  2001-01-25       Impact factor: 9.867

6.  TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma.

Authors:  M Müller; T Schilling; A E Sayan; A Kairat; K Lorenz; H Schulze-Bergkamen; M Oren; A Koch; A Tannapfel; W Stremmel; G Melino; P H Krammer
Journal:  Cell Death Differ       Date:  2005-09-30       Impact factor: 15.828

7.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Authors:  M C Heinrich; D J Griffith; B J Druker; C L Wait; K A Ott; A J Zigler
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

8.  A common E2F-1 and p73 pathway mediates cell death induced by TCR activation.

Authors:  N A Lissy; P K Davis; M Irwin; W G Kaelin; S F Dowdy
Journal:  Nature       Date:  2000-10-05       Impact factor: 49.962

9.  Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.

Authors:  X Luo; I Budihardjo; H Zou; C Slaughter; X Wang
Journal:  Cell       Date:  1998-08-21       Impact factor: 41.582

10.  Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells.

Authors:  M F Romano; A Lamberti; P Tassone; F Alfinito; S Costantini; F Chiurazzi; T Defrance; P Bonelli; F Tuccillo; M C Turco; S Venuta
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

View more
  13 in total

1.  Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.

Authors:  Qing-Li Wu; Ilia N Buhtoiarov; Paul M Sondel; Alexander L Rakhmilevich; Erik A Ranheim
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

Review 2.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

3.  The Roles of P53 and Its Family Proteins, P63 and P73, in the DNA Damage Stress Response in Organogenesis-Stage Mouse Embryos.

Authors:  Nazem El Husseini; Barbara F Hales
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

4.  A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.

Authors:  W G Wierda; J E Castro; R Aguillon; D Sampath; A Jalayer; J McMannis; C E Prussak; M Keating; T J Kipps
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

5.  ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.

Authors:  S H Tonino; J van Laar; M H van Oers; J Y Wang; E Eldering; A P Kater
Journal:  Oncogene       Date:  2010-10-11       Impact factor: 9.867

6.  Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.

Authors:  Sanne H Tonino; Chantal E Mulkens; Jacoline van Laar; Ingrid A M Derks; Guangli Suo; Fransien Croon-de Boer; Marinus H J van Oers; Eric Eldering; Jean Y Wang; Arnon P Kater
Journal:  Leuk Lymphoma       Date:  2015-01-21

7.  Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Authors:  Rosa Lapalombella; Leslie Andritsos; Qing Liu; Sarah E May; Rebekah Browning; Lan V Pham; Kristie A Blum; William Blum; Asha Ramanunni; Chelsey A Raymond; Lisa L Smith; Amy Lehman; Xiaokui Mo; David Jarjoura; Ching-Shih Chen; Richard Ford; Christoph Rader; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

8.  1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.

Authors:  Yingyu Ma; Wei-Dong Yu; Pamela A Hershberger; Geraldine Flynn; Rui-Xian Kong; Donald L Trump; Candace S Johnson
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

Review 9.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

10.  CD137 is induced by the CD40 signal on chronic lymphocytic leukemia B cells and transduces the survival signal via NF-κB activation.

Authors:  Yukana Nakaima; Ken Watanabe; Takatoshi Koyama; Osamu Miura; Tetsuya Fukuda
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.